Wells Fargo & Company Virios Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.31 - $0.84 $0 - $2	3 Added 2.31%	133 $0
Q4 2023 Feb 09, 2024	BUY	$0.46 - $0.9 $2 - $5	6 Added 4.84%	130 $0
Q2 2023 Aug 15, 2023	BUY	$0.35 - $1.94 $1 - $9	5 Added 4.2%	124 $0
Q1 2023 May 12, 2023	BUY	$0.24 - $0.44 $0 - $0	2 Added 1.71%	119 $0
Q4 2022 Feb 13, 2023	BUY	$0.24 - $0.39 $16 - $26	69 Added 143.75%	117 $0
Q3 2022 Nov 14, 2022	SELL	$0.37 - $8.77 $0 - $17	-2 Reduced 4.0%	48 $0
Q2 2022 Aug 12, 2022	BUY	$3.31 - $4.89 $13 - $19	4 Added 8.7%	50 $0
Q1 2022 May 16, 2022	BUY	$4.48 - $6.92 $4 - $6	1 Added 2.22%	46 $0
Q3 2021 Nov 15, 2021	BUY	$4.61 - $6.56 $115 - $164	25 Added 125.0%	45 $0
Q2 2021 Aug 16, 2021	BUY	$4.71 - $6.95 $4 - $6	1 Added 5.26%	20 $0
Q1 2021 May 13, 2021	BUY	$5.01 - $8.84 $95 - $167	19 New	19 $0

1.12M

Ticker VIRI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,330,400
Market Cap $81.4M
Description
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.